Member Info for doze

Discussions with government are not the concern now as it will be a level playing field of test producers on the government register. The issue is who can produce a domestic antigen test for that market. https://www.lse.co.uk/ShareChat.asp?ShareTicker=CAR&share=Carclo&thread=B5ADBA76-A247-43CE-929F-027CC6FC7976&reply=true The above was an interesting post if they supply GAH with the casing for out LFT. I think it might be GAH supplying Calibre atm

" Mahmud Kamani and Richard Hughes have together introduced Simon Wilkinson, a highly experienced software executive and entrepreneur, as a proposed investor and proposed Non-Executive Chairman of the Company."
Simon, Robbo's friend must be Simon Wilkinson. https://www.locationsciencesgroup.ai/investor-relations/significant-shareholders/ https://www.locationsciencesgroup.ai/investor-relations/board-governance/

Medusa is a private company and does not have a need for nda because does not need to issue an rns in the first place and AS respects Medusa's wishes as announced recently.

Sangijuelas1, Robbo did not acknowledge my post specifically but when I pointed out Hughes and Kamani were heavily involved with LSAI Roobo said he played golf with the CEO/Director? who is his neighbour and friend and they even met up for a meal while holidaying on neighbouring islands. BB is for a community of investors and when traders join in the conversation tempers tend to rise.
It is a fact the Medusa connection is important as the millions behind them to support a fledgling diagnostic test distribution business and help manufacture tests is the credibility provided to AVCT AffiDX in the UK for government approval. One of the requirements is ability to verify test result and a medusa connection might be involved here aswell https://find-and-update.company-information.service.gov.uk/company/12783063

Good point A1invest, and if you detect the spike protein you could say you are detecting the nucleocapsid aswell as it is part of the virus and months have imo been spent on ways to include AVCT in the mix

https://s4be.cochrane.org/blog/2015/06/25/testing-diagnostic-tests-sensitivity-specificity/

If AffiDX is procured by DHSC all regulations are deemed to have been met and procurement seems to be imminent judging from the squeeze on supply to https://bioservuk.com/

140 UT @ close

Top poster number 7 atm MrA

links on LSAI chat worth tapping to.

Seems to me when the blackbird customers are thoroughly hooked then bird can be more bullish with the numbers. Traction is starting but maybe many stand to lose their backroom jobs with cloud editing so this is a drag on progress but it is a relentless if slow rollout.

The DHSC are keen to research covid with the intention of validating the jab strategy via antibody testing. The gov is keen to be seen as a very responsible player. It could play well for them as new cases are in the young unvaccinated. I think LFTs will be stocked up on and ours will be one. New stock required shortly.

rns' now have to be tailored to majority shareholders so we will get very lucid reporting. Özaltin owning 53% of Turkey joint ventures.

They could support the Yorkshire Post with a discreet advert for professionals/business LFT use and explain AVA6000 for interest. Stress pricing as 55 euro in Spain will put off punters over there.

https://avacta.com/therapeutics/precision/
It is a gobbledygook webpage however many times I read it. At least Pointbiopharma attempt a proper diagram https://www.pointbiopharma.com/products/tme-technology for their tech while AVCT think dumbing down with symbols will suffice. The public need proper education please, they are stupid if treated as such and AVCT needs for its future to open out from the scientific clique he will encounter in Switzerland next month. There is usually a simple explanation for a science otherwise it would not work.

When AVCT tweeted-I think- "I do like it when a plan comes together" they must have thought something was in the bag. Thwarted by procedure and over committment to Innova by PD and MH probably.

Perhaps they bought them back and after yeserday's miserable price action they thought they would sell them again, reacting as they see fit.

This is riduculous option valuation for a lot of big bio now with all the potential. Always a number of round numbered trades in the thousands so maybe stake building has started. They can all benefit from AVCT by having a stake even if no takeover as prospects are good.

If the standard dose of doxorubicin is used as a start in phase 1 and AVA6000 does deliver all that chemo to the tumour then this could result in many times the normal chemo at the cancer so I would hope prudence prevails and they start with a smaller dose as I would hope this new tech is expected to deliver on its billing.

Excellent bit of recent (13/2/21) work! by one person.
https://www.dovepress.com/understanding-the-molecular-biology-of-sars-cov-2-and-the-covid-19-pan-peer-reviewed-fulltext-article-IDR
https://www.dovepress.com/cr_data/article_fulltext/s306000/306441/img/IDR_A_306441_O_F0001g.jpg